The Westlake Village, Calif.-based biopharmaceutical company filed for Chapter 11 bankruptcy in September after several of its drugs failed to gain approval.
The company, founded in 2010, had hoped to sell itself and restructure but didn’t receive any bids for the whole company. It sold its topical photoparticle therapy assets to Sebacia, a dermatology company, for $1.7 million, according to Bankrupt Company News.
Sienna, which focused on immunology and inflammation treatments, reportedly borrowed hundreds of millions of dollars for research and development, but was never able to bring one of its products to market or generate any revenue.
Read the full article here.
More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
